Litcius/Paper detail

Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial

Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, Sravan Kumar, Anbarasan Sekar, Priyanka Patil, Altaf Siddiqui, Anne Srikanth, Akash Pawar, Sujay Srinivas, Prabhat Bhargava, Seema Gulia, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta

2024The Lancet Oncology41 citationsDOI

Topics & Concepts

MedicineNauseaAntiemeticOlanzapineClinical endpointRegimenVomitingPopulationAprepitantSomnolenceInternal medicineSurgeryAdverse effectRandomized controlled trialPsychiatrySchizophrenia (object-oriented programming)Environmental healthNausea and vomiting managementCancer, Stress, Anesthesia, and Immune ResponseChemotherapy-induced organ toxicity mitigation
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial | Litcius